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Abstract
Cervical cancer is a leading cause of mortality in women worldwide. Staging and management of cervical cancer
has for many years been based on clinical exam and basic imaging such as intravenous pyelogram and x-ray.
Unfortunately, despite advances in radiotherapy and the inclusion of chemotherapy in the standard plan for locally
advanced disease, local control has been unsatisfactory. This situation has changed only recently with the increasing
implementation of magnetic resonance image (MRI)-guided brachytherapy. The purpose of this article is therefore to
provide an overview of the benefits of MRI in the evaluation and management of cervical cancer for both external
beam radiotherapy and brachytherapy and to provide a practical approach if access to MRI is limited.
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Introduction
Cervical cancer is a leading cause of mortality in women
worldwide [1]. The primary treatment of very early stage
disease (IA1-IB1) is surgery and for more advanced dis-
ease (larger IB1-IVA) radiotherapy combined with
chemotherapy [2–6]. Clinical staging based on physical
exam combined with multimodality imaging is of utmost
importance as it determines whether a woman is eligible
for surgery and also describes the extent of the cancer
for women who are not surgical candidates.
Definitive radiation therapy of cervical cancer is one of
the most challenging treatment situations in radiation
oncology requiring application of high radiation doses to
achieve tumor control. However, the geometrical distri-
bution of target volumes in the pelvis with a central
tumor positioned directly between radiosensitive organs
(bladder, rectum, sigmoid and small bowel) and involved
or at risk lymph nodes neighboring small bowel are chal-
lenging for external beam therapy. High radiation doses
can therefore typically not be delivered by external beam
radiotherapy alone and necessitate an additional brachy-
therapy boost.
Traditionally, the brachytherapy boost has been deliv-
ered with tandem-based applicators using 2D x-ray
planning with a pear-shaped dose distribution prescribed
to Point A. However, comparisons of point-based 2D
planning with volumetric-based 3D planning show poor
correlation between point doses and both coverage of
clinical target volumes as well as doses to organs at risk
(OARs), indicating a clear need for improved image
guidance and soft tissue-based information to guide the
planning process [7].
With its excellent soft tissue imaging characteristics,
magnetic resonance imaging (MRI) now plays an im-
portant role in many aspects of tumor staging, planning
and delivery of radiotherapy, post treatment response as-
sessment and surveillance [8–10]. MRI is well known to
have superior soft tissue imaging characteristics and
shows excellent results in determining local disease ex-
tent compared to physical exam and other 3D imaging
techniques [11, 12]. For women who are managed with
primary radiotherapy, MRI also provides clear
visualization of the cervical tumor in multiple planes
allowing for a reliable volumetric definition of the target
volume both for external beam and brachytherapy treat-
ment planning [9]. Particularly, with the addition of MRI
to brachytherapy planning, tumor control rates are sig-
nificantly improved [13–15]. Additionally, MRI is very
useful in determining response to treatment after a
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course of chemoradiation, as well as determining late ef-
fects in the normal tissues [10, 16, 17].
Logistically, it is often difficult to obtain MRIs on cer-
vical cancer patients at multiple time points during
treatment. However, there are workarounds that are
practically useful for centers without dedicated MR
scanners in their department. There are promising new
directions in the realm of MR imaging with increased
use of morphological and functional MRI for adaptive
radiotherapy and promising results showing better
evaluation of treatment response and improved out-
comes for patients [18–21]. The purpose of this article is
to review the benefit of MRI for radiotherapy of cervical
cancer and provide recommendations for use of MRI
that are applicable to daily practice.
MRI for pre-treatment assessment of cervical cancer
The International staging system for cervical cancer is
based on clinical exam, as the primary management is
typically non-surgical. The only modalities included in
the International Federation of Gynecology and Obstet-
rics (FIGO) staging system are physical exam, cystos-
copy, proctoscopy, intravenous urography and x-rays.
However, where imaging resources are more widely
available MRI, computed tomography (CT) and positron
emission tomography (PET/CT) are used for their ana-
tomical detail, to guide treatment planning and provide
prognostic information.
MRI has become a key component of initial staging
for cervical cancer due to the superior soft tissue delin-
eation of pelvic structures. For women with early-stage
cervical cancers, MRI is helpful for determining the ap-
propriateness of surgery verses primary chemoradiation.
In fact, several studies using pre-operative MR imaging
have demonstrated that in patients with early-stage inva-
sive cervical tumors (<3 cm, confined to the cervix) MRI
has a 94 % accuracy and 95 % negative predictive value
for determining parametrial invasion at the time of diag-
nosis. Using MRI with fast spin-echo (FSE) T2-weighted
technique it was possible to determine who should be
managed surgically and who should be managed with
chemoradiation in order to try to avoid tri-modality
therapy with its known complications [22–25].
For women who were planned for curative surgery, the
prospective ACRIN 6651/GOG 183 Intergroup study
used MRI and CT pre-operatively and showed that in
patients with stage ≥ IIB MRI had the highest sensitivity
for disease detection (53 %) compared to CT (42 %) and
FIGO clinical stage (29 %) [12]. From the same group of
patients, MRI was found to be better than CT and clin-
ical exam for evaluating uterine body involvement and
measuring tumor size, but neither were good for stromal
invasion. In a retrospective analysis of the same study,
interobserver variability was assessed between CT and
MRI for diagnostic accuracy. MRI showed higher inter-
rater agreement as well as better tumor visualization
and detection of parametrial invasion [11].
For women with larger primary tumors where chemo-
radiation is the preferred definitive treatment, MRI is
helpful in determining pelvic extent of disease in order
to plan for radiation treatments and may even obviate
the need for more invasive procedures such as exam
under anesthesia [26, 27]. Recent guidelines for
staging of cervical cancer using MRI published by
the European Society of Urogenital Radiology recom-
mend MRI for staging tumors that are clinically at
least IB1 and also for smaller tumors if fertility pre-
serving surgery is a consideration. They recommend
getting images in at least 2 planes (sagittal, coronal, axial)
with T2 weighted sequences as this best detects
extension into uterus, parametria and adjacent organs
(Table 1) [8].
Table 1 Recommended MR imaging
MR study Plane orientation EBRT BT Follow up
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In nearly all cases, MRI provides additional information
to standard clinical exam, CT and PET/CT imaging as it
allows improved assessment of the extent of primary
tumor disease, particularly to determine tumor diameter
and infiltration of the parametria. This information is im-
portant to denote prior to embarking on definitive man-
agement, either surgically or with chemoradiation.
MRI for external beam radiotherapy planning
The most clinically relevant benefit of MRI for cervical
cancer planning lies in the clear visualization of the cer-
vical tumor in multiple planes allowing for a reliable
volumetric definition of the target volume.
Traditionally, the pelvic treatment fields for cervical
cancer were designed based on bony landmarks using
2D planning. However, early studies with MR imaging
assessed tumor coverage with standard pelvic fields, and
it was observed that aligning to bony anatomy resulted
in tumor miss in up to 66 % [28–31]. As treatments are
becoming more conformal, MRI is needed to ensure that
the target is adequately covered.
For treatment planning, MRI should be performed in
the same position as the planned treatment, either using
an MR simulation or with co-registration of images to a
CT simulation. Images should be obtained with 1.5-3 T
scanners with body coils. To control for peristaltic mo-
tion 0.5 mg glucagon IV can be given prior to and half-
way through the exam. In general, multiplanar T2
weighted images are most helpful for defining both the
target and OARs (Table 1) [9].
Recently, there have been contouring guidelines issued
for external beam planning of cervical cancer by both
the Gynecologic IMRT Consortium and the Japanese Ra-
diation Oncology Group (JCOG). These guidelines each
recommend delineation for both target and OARs on T2
weighted MRI and demonstrated that compared with
contouring on CT, contouring on MRI showed improved
reproducibility among experts, particularly in the region
of the parametrium. Both groups acknowledged that most
physicians use primarily CT-based planning, but the con-
sensus was that for conformal planning T2-weighted MRI
was strongly recommended [32, 33]. Based on these find-
ings, MRI in treatment position has become a standard
imaging procedure for 3D conformal and intensity modu-
lated external beam treatment planning [34].
Another factor that strongly influences external beam
treatment precision is the large inter- and intrafraction
mobility of pelvic organs that affect both target volume
dose coverage and dose to sensitive OARs. MRI is par-
ticularly useful to measure motion variability due to its
excellent soft tissue visualization, the absence of radi-
ation, the availability of multiplanar imaging and fast 4D
imaging. Using serial MRIs during external beam radi-
ation for cervical cancer demonstrates that the uterus,
cervix, vagina and even pelvic lymph nodes have consid-
erable motion between treatments due to changes in
bladder filling, rectal filling and other internal motion.
Uterine motion is the most significant of these, with
average interfraction motion of 7 mm in the superior to
inferior and anterior to posterior directions [35]. Intra-
fraction motion has also been shown of up to 10 mm for
the CTV when using sequential MRI for patients, even
when done within 16 min of each other [36]. However,
to compensate for the observed organ motion, large
CTV and PTV margins are needed and result in inclu-
sion of large volumes of normal tissue in the target vol-
ume causing potentially detrimental side effects that
reduce the overall therapeutic ratio. Various solutions
have been suggested, e.g. anisotropic and tapered
population-based margins with larger margins at the
fundus compared to the cervix, individualized margins
based on the observation of large interpatient variations
[37, 38]. A more practical solution is to incorporate
intrafraction and interfraction MRI-guided soft tissue
registration with adaptation of the treatment plan to ad-
just for the observed variations [36].
MRI for brachytherapy planning
While MRI for external beam treatment planning is still
in development, over the last years the availability of
MRI has transformed brachytherapy for cervical cancer.
With improved visualization of the residual tumor ex-
tent at the time of brachytherapy, new applicators with
interstitial needles have been added to the existing rep-
ertoire of applicators to cover particularly lateral exten-
sions of tumor into the parametria that would have been
under dosed with classical applicator configurations [39].
In addition, a new MRI-based nomenclature of target
volumes has been introduced in parallel with new
guidelines for dose reporting created by The Groupe
Européen de Curiethérapie and the European Society
for Radiotherapy & Oncology (GEC-ESTRO). This
working group was founded in 2000 to support, promote
and standardize 3D based treatment planning for cervical
cancer brachytherapy and have thus far 4 parts to the
guidelines that focus on various aspects of MRI-based 3D
brachytherapy. The new guidelines and MR imaging
facilitate individualized treatment planning for brachy-
therapy, a process called MR image-guided adaptive
brachytherapy [40–42].
MRI guided brachytherapy allows for a transition from
prescribing uniformly to point A to targeting the re-
sidual disease in the cervix and paracervical tissues at
the time of brachytherapy. The first part of the GEC-
ESTRO working group recommendations created a
common language for contour definition and prescrip-
tion volumes at the time of brachytherapy. The GTV is
defined by the clinical examination in addition to the
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high signal intensity regions in the cervix and paracervi-
cal region on FSE T2 weighted MRI. The GTV should
be identified at diagnosis (GTVD) and at each brachy-
therapy insertion (GTVB1, GTVB2, etc.) to determine the
tumor response and identify the regions at highest risk
at the time of brachytherapy. The high risk CTV (HR
CTV) is the region surrounding the GTV, including the
whole cervix, with the highest risk of local recurrence
due to residual macroscopic disease at the time of
brachytherapy. The intermediate risk CTV (IR CTV) is a
further extension of the HR CTV with a margin of 5-15
mm to encompass the region at risk for microscopic re-
sidual disease. The GEC-ESTRO recommendations are
to prescribe to the HR CTV with no PTV margins.
Ideally the IR CTV would receive at least 60Gy [41].
In the second working group guidelines, dose volume
parameters are described for each of the target volumes
described above as well as OARs. These parameters
allow conversion from point-based prescriptions to 3D
prescriptions and give recommendations for data collec-
tion for each brachytherapy application, including re-
cording doses at point A as well as D100 and D90 (dose
to 100 and 90 % of the volume) for GTV, HR CTV and
IR CTV, respectively [42]. Additionally, instead of point
doses for OARs, D0.1cc, D1cc, D2cc are recorded and can
be converted into the biologically equivalent dose in 2Gy
fractions (EQD2) for addition to dose from external
beam radiotherapy [43].
For these parameters to adequately be assessed and re-
corded, the MR imaging must be of a similar quality at
each time point, using a 1.5-3 T magnet, surface pelvic
coils, and patient preparation to minimize internal and
external motion. For brachytherapy imaging with the ap-
plicator in place the recommended imaging includes T2
FSE in the para-axial, para-sagittal and para-coronal (ac-
cording the cervix). In addition to the GTV, the OARs
including the bladder, rectum, sigmoid and vagina are
best contoured on the T2 weighted sequences [44]. For
applicator reconstruction, para-transverse MR imaging is
optimal with slice thickness ≤5 mm [45].
With the introduction of the GEC-ESTRO guidelines,
many institutions have started using IGABT with MRI.
Using these guidelines, with delineation of the GTVBT,
HR CTV and IR CTV, due to more accurate assessment
of residual disease at the time of the boost studies show
considerable improvements in tumor control and reduc-
tions in normal tissue complications (Table 2). The
Vienna group prospectively evaluated their results using
MR IGABT during the years 2001–2008 and compared
outcomes with CT assisted brachytherapy treatment
planning during 1993–1997 and found an absolute local
control benefit of 23–26 % and a relative reduction in
local failure of 65 % [13]. These results have been repli-
cated at other institutions, as shown in Table 2, with local
control rates at 2 and 3 years of >90 %. Additionally,
publications from Denmark and the Netherlands have
shown that compared to conventional planning MR
IGABT improves overall survival from 51-63 % with
conventional planning to 79–86 % with the MR IGABT
technique [14, 15]. With improved targeting, there has
also been a reduction in treatment-related side effects with
minimal severe late toxicity [13–15, 46–48].
A recent publication from the European study on
MRI-guided brachytherapy in locally advanced cervical
cancer (EMBRACE) describes women with FIGO IIB
and IIIB disease as having either an infiltrative or expan-
sive pattern of parametrial growth based on imaging
characteristics. With repeat MR imaging at the time of
brachytherapy, they found that women with infiltrative
growth patterns had less response of their parametrial
disease, but when using IGABT they were able to en-
compass gross disease into the HR CTV [49]. Further
results from this large patient group are expected over
the next several years (https://www.embracestudy.dk/).
With the ability to contour the target in 3D, it has be-
come clear that previous fixed-geometry applicator
based methods with point-based planning either deliv-
ered too large dose volumes for small and too small dose
volumes for large tumors resulting in the risk of over-
dosing of normal tissues on the one side and under dos-
ing the tumor on the other [7, 50, 51]. Even in small
tumors, MRI-guided brachytherapy was found to reduce
dose to the highest exposed 2 cc volumes (D2cc) to nor-
mal tissues by 12–32 % [52].
Table 2 Studies using MR image-guided adaptive brachytherapy with outcomes
Study Pts Type of imaging for BT planning Follow up (years) LC (%) DFS (%) OS (%)
Simpson et al. (2015) [47] 76 CT62 % had MRI with second fraction 2 94 70 75
Gill et al. (2015) [46] 128 MRI first fraction and then CT 51.6 %MRI 48.4 % 2 91.6 81.8 87.6
Rijkmans et al. (2014) [15] 8343 MRI vs.x-ray 3 9368 8651
Lindegaard et al. (2013) [14] 14099 MRI vs.x-ray 3 91 7963
Nomden et al. (2013) [48] 46 MRI 3 93 71 65
Potter et al. (2011) [13] 156 MRI 3 95 75 68
LC Local control, DFS Disease free survival, OS Overall survival
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Despite the improved soft tissue visualization with
MRI, many physicians are less familiar with the target
delineation on MRI and recent comparison between
CT and MRI contouring at the time of brachytherapy
showed more agreement among experts with CT-
based contours [53]. However, MRI was more accur-
ate for patients with larger tumors, parametrial exten-
sion, or those with regression after external beam
radiotherapy. Compared to MRI, CT has shown to
produce large overestimation of residual disease at
the time of brachytherapy and may therefore result in
unnecessary dose to OARs [54].
MRI for evaluation of treatment response
MRI has been applied clinically to determine the need
for additional surgical salvage in the presence of residual
tumor early after radiation therapy as well as to detect
tumor recurrence during post treatment follow up. MRI
has excellent accuracy in assessing residual tumor both
for central recurrences in the vagina and cervix as
well as tumor recurrences in the parametria and
pelvic side walls that are difficult to detect with clinical
exam [16]. In fact, the diagnostic ability to detect residual
disease was found to be superior with MRI compared
to PET with positive and negative predictive values
for 74 % and 100 % for MRI compared with 44 %
and 44 % for PET [17].
Similarly to other imaging modalities, the challenge
with identifying tumor recurrence on MRI is differen-
tiating between tumor and post therapy sequelae such
as fibrosis, inflammation and necrosis. If obtained
within 3–8 weeks post-treatment high false positive
rates were observed, likely related to ongoing inflam-
matory changes [55]. A longer interval (>6 months)
between treatment and post therapy assessment has
shown improved reliability to correctly identify tumor
recurrence [10].
Logistical Issues with MRI
One of the primary logistical issues with MRI for radio-
therapy planning comes from limited access to MR scan-
ners. While MRI simulation and real time MRI at the time
of brachytherapy applicator insertion would be desirable
for guidance, for many radiation oncology departments,
MRI scans are obtained in the diagnostic radiology
department for initial treatment planning and again
after the applicator has already been inserted prior to
the first brachytherapy session (Figs. 1 and 2) [9, 56].
Ideally, MRI would be obtained with the applicator in
place at each brachytherapy procedure. Several groups
have recently published on workarounds for depart-
ments without dedicated MRI scanners (Fig. 3) [57, 58].
Performing both MRI and CT for the first brachytherapy
fraction and then subsequent CT only imaging with
registration to prior MRI is comparable to using MRI
based planning for each fraction of brachytherapy. How-
ever, for larger tumors or for unfavorable geometry with
organs at risk, MRI planning is still felt to be the gold
standard [59, 60].
Despite of the benefits of MRI, there are some patients
who are unable to have MR imaging. For example, pa-
tients with metallic implants, pacemakers, severe claus-
trophobia or a very large body habitus. In those patients,
CT-based planning appears a reasonable alternative to
MRI-based planning, as recently demonstrated in a large
cohort of women treated with CT-guided brachytherapy
planning with or without additional MRI. In this series of
76 women, 17 % had MRI prior to the first brachytherapy
procedure without the applicator in place and 62 % had
an MRI at the time of the second insertion with the appli-
cator in place. Due to logistical issues with obtaining MRI,
21 % of patients were planned with CT alone. The 2 year
local control was 94.2 %, disease free survival 75 % and
overall survival 73 %, which is comparable to the results in
the MR IGABT series in Table 2 [47].
Fig. 1 Axial T2 weighted MR images. a: Pre-treatment image with large cervical tumor. b: Pre-brachytherapy image showing excellent response
to treatment with small focus of residual signal intensity. c: Simulated brachytherapy plan with GTV contoured (yellow) and plan adjusted to cover
residual disease with 100 % isodose line (green) using tandem and ovoid applicators
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Various challenges from medical physics perspective in-
clude the need for MR image registration with CT images
for dose calculation, the effect of MR image distortion on
geometrical accuracy, problems with intracavitary applica-
tor visibility, susceptibility artifacts and reconstruction er-
rors, and the need for MRI-compatible titanium or plastic
applicators [39, 61].
Another limitation to the widespread use of MRI-
based evaluation and treatment planning with MRI is
physician discomfort with target and organ identification
and target delineation in this platform. Many physicians
are also less familiar with 3D treatment planning for
brachytherapy and prefer using point-based planning.
However, with the increased availability of clear guide-
lines in the literature as well as Continuing Medical
Education (CME) opportunities to learn at the ABS
GYN School and ASTRO contouring sessions, this will
change over time [41, 42, 62–64].
Future directions for the use of MRI in cervical cancer
Cervical cancer offers many opportunities for adaptive
radiotherapy approaches with the goals of improving
dose conformality, reducing normal tissue toxicity and
potentially increasing tumor dose to areas of residual
disease. These goals can be achieved by adjusting the
dose plan based on individual patient characteristics of
tumor volume regression, tumor motion and set up repro-
ducibility. MRI plays an important role in the develop-
ment of adaptive radiotherapy as it provides 3D
information about organ motion and tumor volume
shrinkage [35, 36, 65]. MRI-guided adaptive brachytherapy
essentially has already incorporated the adaptive concept
by adjusting the MRI-based brachytherapy dose plan of
each fraction to the individual patient 3D imaging infor-
mation obtained prior to each fraction [13, 15].
For external beam radiotherapy, no routine strategies
of treatment adaptation have been established in clinic,
Fig. 2 Sagittal T2 weighted MR images. a: Pre-treatment image with large cervical tumor. b: Pre-brachytherapy image with good response, but
still large residual disease. c: Simulated brachytherapy plan with GTV contoured (yellow) and inadequate coverage with tandem and ovoids.
d: Simulated plan with tandem and interstitial needles with excellent target coverage with 100 % isodose line (green)
Fig. 3 Work flow with incorporation of MRI with the GEC-ESTRO “gold standard” and 2 alternative approaches for limited MRI availability with MRI
after 1st BT and MRI pre-BT with mock planning
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in part due to challenges in deformable dose accumu-
lation, the speed of adaptive re-planning, and limited
resources. Inter- and intrafraction organ motion and
tumor shrinkage offer various opportunities to adjust
the individual plans to these parameters. Most of the
tumor regression occurs during external beam radio-
therapy with large interpatient variation in regression
rates [66]. Depending on the timing of brachytherapy
relative to external beam therapy, initial tumor vol-
umes are reduced often by ≥80 % at the time of
brachytherapy [16, 67–69]. Due to this large change
in tumor volume, adaptive strategies are expected to
increase the therapeutic ratio by enabling delivery of
additional boost doses to residual tumor in the pelvic
lymph nodes [70], residual central tumor [71, 72], or
by selective sparing of high dose to organs at risk.
With MRI-linear accelerator development on the hori-
zon, real-time MR imaging during treatment will allow
for excellent soft tissue delineation, image fusion, rapid
adaptive radiation planning, and improved tumor target-
ing for women with cervical cancer.
While morphological MRI has become a standard im-
aging method for cervix cancer radiotherapy, more re-
cently, functional MRI sequences have been investigated
as biomarkers for determination of radioresistance.
Diffusion-weighted MRI (DW-MRI) is a non-contrast
imaging methodology that measures water diffusion in
tissue typically using apparent diffusion coefficients
(ADC) for quantification and comparison. ADC values
are lower in tumor than normal tissue due to higher
cellularity and can subsequently increase as a result
of therapy due to apoptosis and cell death, as well as
inflammation and microvascular leakage [73–75]. Sev-
eral small studies investigated DW-MRI in radiother-
apy of cervical cancer and observed that ADC change
early during radiotherapy predicts tumor response on
MRI and is associated with overall survival [18–20]. It
was also noticed that patients with high initial ADC
values had worse outcomes than patients with lower
ADC values, likely due to necrotic areas that were
hypoxic and therefore radioresistant [76, 77]. Fluoro-
deoxyglucose (FDG) PET standard uptake value max-
imum and DW-MRI (ADC mininum) were found to
be complementary prognostic factors for cervical can-
cer [78, 79]. However, DW-MRI is not routinely used
in radiotherapy due to lack of larger clinical valid-
ation of results and lack of integration into the radio-
therapy workflow [80].
Dynamic contrast-enhanced MRI (DCE MRI) is as-
sumed to show vascular density and perfusion which is
thought to be correlated with hypoxia and radioresis-
tance. Changes in signal intensity indicating increasing
tumor perfusion and volume change after 2–2.5 weeks
of therapy predict local tumor control and survival [21].
In a large study with repeated DCE MRI before and
during therapy, functional risk volumes were generated
for subvolumes with critically low DCE signal. Larger
functional risk volumes predicted tumor control and
disease free survival before and during therapy. In fact,
DCE MRI was a better predictor than anatomical volume
change [81, 82].
Further new imaging methods under investigation
include blood-oxygen level dependent (BOLD) MRI
[83] and diffusion-weighted high-resolution magic angle
spinning magnetic resonance spectroscopy (MRS) [84].
Conclusions
Magnetic resonance imaging has been generating clinical
interest for use in cervical cancer, but there has yet to be
a comprehensive clinical review with practical informa-
tion on the use of MRI for patients with cervical cancer.
Using MRI, patients can be more accurately staged and
guided towards the correct management options. For pa-
tients that require radiation therapy, MRI shows excel-
lent soft tissue delineation and should be incorporated
into both external beam and brachytherapy treatment
planning. Ideally, availability of an MR scanner in the ra-
diation oncology department is the most convenient, but
even without dedicated scanners, obtaining MR imaging
is practical and can be used for more accurate treatment
planning and delivery. In the future, MRI will likely
become even more prevalent as deformable dose registra-
tion, adaptive imaging for external beam and functional
imaging become more established.
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